What is the role of tyrosine kinase inhibitors in the etiology of macrocytosis?

Updated: Dec 16, 2018
  • Author: Vincent E Herrin, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

The tyrosine kinase inhibitors sunitinib and imatinib have been shown to induce macrocytosis in patients with a variety of cancers, including renal cell carcinomas (RCCs), gastrointestinal stromal tumors (GISTs), and breast cancer. [12] In patients with RCC, the development of macrocytosis following the institution of sunitiinib treatment may potentially serve as a positive prognostic factor for overall survival.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!